Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Abstract:

:Coronary arterial thrombolysis is becoming an established treatment of acute myocardial infarction. If given early enough, it recanalises occluded coronary arteries, salvages myocardial function and reduces mortality. A reduction of mortality in patients with acute myocardial infarction has now been demonstrated for streptokinase, anisoylated plasminogen streptokinase activator complex (APSAC; anistreplase) and recombinant tissue-type plasminogen activator (rt-PA). From the biochemical point of view, rt-PA has several attractive properties. It is similar to or identical with the physiological plasminogen activator in blood, it does not induce an antibody response, and it is more fibrin-specific than most or all other currently known thrombolytic agents. The rate of recanalisation of occluded coronary arteries with rt-PA is about 60 to 80% in non-comparative and placebo-controlled trials. rt-PA was similar in efficacy to urokinase in the only trial to compare the 2 agents. In 2 comparative trials evaluated by meta-analysis, rt-PA appeared more effective than streptokinase for the early recanalisation of occluded arteries. Both agents were comparable in their effects on left ventricular function in 2 comparative trials, but further study is needed to conclusively evaluate this parameter. Moreover, both agents reduce inhospital mortality, but much larger direct comparative trials are required before scientifically valid statements can be made on the relative clinical efficacy of available thrombolytic agents in terms of their effects on both morbidity and mortality. Thus, rt-PA constitutes a notable contribution of recombinant DNA technology to the treatment of thromboembolic disease, the main cause of death and disability in Western societies.

journal_name

Drugs

journal_title

Drugs

authors

Collen D,Lijnen HR,Todd PA,Goa KL

doi

10.2165/00003495-198938030-00003

subject

Has Abstract

pub_date

1989-09-01 00:00:00

pages

346-88

issue

3

eissn

0012-6667

issn

1179-1950

journal_volume

38

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Correction to: Isatuximab: First Approval.

    abstract::In the table 'Key clinical trials of isatuximab (Sanofi)', in the left-hand column. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-020-01325-9

    authors: Dhillon S

    更新日期:2020-06-01 00:00:00

  • Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.

    abstract::Sulbactam is a semisynthetic beta-lactamase inhibitor which when combined with certain beta-lactam antibacterials extends their activity against bacteria that are normally resistant to the antibiotic due to production of beta-lactamases. In combination with ampicillin it extends the antibacterial activity of ampicilli...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198733060-00003

    authors: Campoli-Richards DM,Brogden RN

    更新日期:1987-06-01 00:00:00

  • Cenobamate: First Approval.

    abstract::Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset s...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01250-6

    authors: Keam SJ

    更新日期:2020-01-01 00:00:00

  • The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.

    abstract::The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is implicated in the pathogenesis of lymphoma. Deeper understanding of the diversity and biological impact of this pathway has led to the development of specific inhibitors to this pathway. Preclinical data in cell lines, patient samples and disease models have bro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0565-4

    authors: Seiler T,Hutter G,Dreyling M

    更新日期:2016-04-01 00:00:00

  • Drug treatment of hypertension.

    abstract::There are several first choices for the treatment of mild and moderate hypertension. The selection of a drug may be influenced by concomitant pathology, with positive indications for particular drugs, e.g. coexistent angina, indicating use of a beta-receptor blocking drug or calcium antagonist; fluid retention indicat...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800356-00006

    authors: Prichard BN

    更新日期:1988-01-01 00:00:00

  • Pharmacotherapy for oesophagogastric cancer.

    abstract::Gastric cancer is the seventh and oesophageal cancer the ninth most common cancer in the UK, and >50% of patients present with locally advanced or metastatic disease. The incidence of oesophageal and oesophagogastric junctional tumours is increasing, making these important disease entities to understand and research. ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767170-00006

    authors: Jackson C,Starling N,Chua YJ,Cunningham D

    更新日期:2007-01-01 00:00:00

  • Reduction of prostaglandin E2 concentrations in synovial fluid of patients suffering from rheumatoid arthritis following tiaprofenic acid or indomethacin treatment.

    abstract::Prostaglandin E2 (PGE2) is a potent stimulator of inflammation, and the inhibition of its synthesis is one possible mechanism of action of non-steroidal anti-inflammatory drugs (NSAIDs). We have investigated patients suffering from rheumatoid arthritis to determine how synovial fluid levels of PGE2 are affected by tia...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800351-00004

    authors: Daymond TJ,Rowell FJ

    更新日期:1988-01-01 00:00:00

  • Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.

    abstract::Nizatidine is an H2-receptor antagonist which in animal studies was more active on a weight-for-weight basis than cimetidine in inhibiting basal and stimulated gastric acid secretion. Similarly, studies in humans have confirmed that nizatidine is a potent inhibitor of basal, nocturnal and stimulated gastric acid secre...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198836050-00002

    authors: Price AH,Brogden RN

    更新日期:1988-11-01 00:00:00

  • Current concepts in diabetic gastroparesis.

    abstract::Diabetic gastroparesis is a common and debilitating condition affecting millions of patients with diabetes mellitus worldwide. Although gastroparesis in diabetes has been known clinically for more than 50 years, treatment options remain very limited. Until recently, the scientific literature has offered few clues rega...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363130-00002

    authors: Smith DS,Ferris CD

    更新日期:2003-01-01 00:00:00

  • Antiviral therapy in human immunodeficiency virus infections. Current status (Part I).

    abstract::Antiviral therapy has in the past met with limited success and only a few antiviral drugs have been available. The human immunodeficiency virus (HIV) epidemic has created an urgent need for the development of antiviral therapy against this infection. HIV replication offers several targets for inhibitory compounds, the...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199345040-00002

    authors: Sandström E,Oberg B

    更新日期:1993-04-01 00:00:00

  • Protein binding displacement interactions and their clinical importance.

    abstract::The binding of drugs to proteins is an important pharmacokinetic parameter. Many methods are available for the study of drug protein binding phenomena and there are also many ways to interpret the binding data. Although much emphasis has been placed on the binding of drugs in the plasma, binding also takes place in th...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198325050-00003

    authors: McElnay JC,D'Arcy PF

    更新日期:1983-05-01 00:00:00

  • Drotrecogin alfa (activated).

    abstract::Drotrecogin alfa (activated), recombinant human activated protein C, inhibits coagulation and inflammation and promotes fibrinolysis in patients with severe sepsis. 850 patients with severe sepsis treated with intravenous drotrecogin alfa (activated) 24 microg/kg/h for 96 hours had a significantly greater reduction in...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-200262040-00006

    authors: Lyseng-Williamson KA,Perry CM

    更新日期:2002-01-01 00:00:00

  • Pancreatic islet cell transplantation: likely impact on current therapeutics for type 1 diabetes mellitus.

    abstract::Pancreatic islet transplantation as a cell-based treatment for diabetes mellitus has been pursued for over quarter of a century, ever since the first successful use of this approach to cure diabetes mellitus in rodents in the 1970s. However, even though autoislet intrahepatic transplantation in patients with chronic p...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200161140-00001

    authors: Robertson RP

    更新日期:2001-01-01 00:00:00

  • Optimum management of postoperative pain.

    abstract::After surgery, patients try to minimise discomfort by various manoeuvres including change of posture, immobilisation of injured areas and use of analgesic drugs. The characteristic finding with drug use, revealed by permitting patients to titrate themselves with analgesic from a machine, is that the interindividual do...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198529040-00004

    authors: Bullingham RE

    更新日期:1985-04-01 00:00:00

  • Assessment of the risk-benefit ratio for antiarrhythmic drug use.

    abstract::Arrhythmia treatment has always been difficult, particularly as there are no good indicators of the optimal management strategy. The introduction of new antiarrhythmic agents has forced reappraisal of how these drugs are used. Dynamic electrocardiography and invasive electrophysiological studies are important tools fo...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198836050-00005

    authors: Campbell RW

    更新日期:1988-11-01 00:00:00

  • Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.

    abstract::Exenatide extended-release (exenatide ER) [Bydureon(®)] is a glucagon-like peptide-1 receptor agonist, approved for the treatment of type 2 diabetes mellitus. It is injected subcutaneously by patients once weekly, with no dose titration required. This article updates an earlier review of exenatide ER in the management...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0420-z

    authors: Syed YY,McCormack PL

    更新日期:2015-07-01 00:00:00

  • Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection.

    abstract::Stavudine is a nucleoside analogue which undergoes intracellular phosphorylation to its active metabolite, stavudine-5'-triphosphate. At clinically relevant concentrations, the active metabolite restricts HIV replication by inhibiting the inclusion of thymidine-5'-triphosphate into proviral DNA by HIV reverse transcri...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199651050-00009

    authors: Lea AP,Faulds D

    更新日期:1996-05-01 00:00:00

  • Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.

    abstract::Eplerenone (Inspra) is a selective aldosterone blocker. Oral eplerenone is approved for use in patients with left ventricular (LV) systolic dysfunction and clinical evidence of heart failure following acute myocardial infarction (MI) in the US and in European countries (e.g. the UK and The Netherlands). The addition o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464230-00005

    authors: Keating GM,Plosker GL

    更新日期:2004-01-01 00:00:00

  • Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.

    abstract::Aripiprazole (Abilify®) is an atypical antipsychotic indicated for the treatment of mania associated with bipolar I disorder. It is unique in its class, as it is a partial agonist of dopamine D(2) and D(3), and serotonin 5-HT(1A) receptors and a modest antagonist of 5-HT(2A) receptors. This article reviews the pharmac...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208320-000000000-00000

    authors: Dhillon S

    更新日期:2012-01-01 00:00:00

  • Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.

    abstract::Irinotecan (CPT-II) is a semisynthetic derivative of camptothecin. It and other camptothecin analogues/derivatives appear to exert their antitumour activity by binding to topoisomerase I. The active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), has demonstrated potent growth inhibition of human col...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652040-00013

    authors: Wiseman LR,Markham A

    更新日期:1996-10-01 00:00:00

  • Medication for hyperkinetic children.

    abstract::The hyperkinetic syndrome is a symptom complex of hyperactivity, short attention span, distractibility, impulsivity, learning difficulties, other behaviour problems and 'equivocal' neurological signs. However, none of these terms has ever been objectively defined and at present diagnosis is largely a matter of clinica...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197611020-00001

    authors: Werry JS

    更新日期:1976-01-01 00:00:00

  • Current management of mantle cell lymphoma.

    abstract::Mantle cell lymphoma is a rare yet well defined subtype of B-cell non-Hodgkin's lymphoma. The correct histological diagnosis of this lymphoma subtype is of the utmost importance; however, it is also a very difficult diagnosis. Clinical management is often complex, and despite the successful introduction of monoclonal ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767120-00004

    authors: Weigert O,Unterhalt M,Hiddemann W,Dreyling M

    更新日期:2007-01-01 00:00:00

  • HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk.

    abstract::HMG-CoA reductase inhibitors (statins) have been shown to reduce mortality and cardiovascular morbidity in patients with hyperlipidaemia and those with coronary artery disease. However, evidence for statin treatment in patients with chronic heart failure (CHF) remains a subject of debate. Patients with heart failure w...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666020-00002

    authors: Laufs U,Custodis F,Böhm M

    更新日期:2006-01-01 00:00:00

  • Drugs for cardiovascular disease prevention in women: implications of the AHA Guidelines--2007 Update.

    abstract::Lifestyle interventions constitute the initial strategy for the primary and secondary prevention of cardiovascular disease in women. However, pharmacotherapy is often indicated for control of major cardiovascular risk factors, and abundant clinical trial data support the morbidity and mortality benefit of a number of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868030-00006

    authors: Wenger NK

    更新日期:2008-01-01 00:00:00

  • An overview of the long-term safety experience of nabumetone.

    abstract::Safety data have been gathered in US clinical trials of nabumetone on 1912 patients from August 1981 to May 1988. Dosing in the double-blind trials was 100 mg at bedtime, but in open-label trials patients could increase the dosage of nabumetone to 1500 or 2000 mg if required. Adverse experiences reported in the double...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-199000405-00008

    authors: Willkens RF

    更新日期:1990-01-01 00:00:00

  • Current status of dopamine agonists in Parkinson's disease management.

    abstract::The occurrence of late side effects of long term levodopa therapy (fluctuations in motor performance, abnormal movements, and symptoms unresponsive to dihydroxyphenylalanine) led to the search for novel anti-Parkinsonian drugs. Dopamine agonists are one of the newer families of anti-Parkinsonian agents, and they inclu...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199346030-00005

    authors: Montastruc JL,Rascol O,Senard JM

    更新日期:1993-09-01 00:00:00

  • The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications.

    abstract::Resistance to the metabolic actions of insulin is thought to play a determining role in the aetiology of a great variety of disorders, including essential hypertension, accelerated atherosclerosis and cardiomyopathies. ACE inhibitors are recognised as being highly effective therapy for hypertension and cardiac insuffi...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262090-00002

    authors: Bernobich E,de Angelis L,Lerin C,Bellini G

    更新日期:2002-01-01 00:00:00

  • The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men.

    abstract::Roxatidine acetate (HOE 760, TZU 0460) is a new H2-receptor antagonist which is more potent than cimetidine and ranitidine. A randomised, double-blind, placebo-controlled study was conducted in healthy men to determine the effects of multiple oral doses of roxatidine acetate on unstimulated gastric acid secretion, and...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800353-00011

    authors: Lassman HB,Ho I,Puri SK,Sabo R,Scheffler MR

    更新日期:1988-01-01 00:00:00

  • Semaglutide: First Global Approval.

    abstract::Novo Nordisk has developed a subcutaneous formulation of semaglutide (Ozempic®), a modified human glucagon-like peptide-1 (GLP-1) analogue, for the treatment of type 2 diabetes mellitus. It has been developed using Novo Nordisk's proprietary protein-acylation technology, and is administered using an injection device. ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0871-0

    authors: Dhillon S

    更新日期:2018-02-01 00:00:00

  • Drug-induced hypertension: pathogenesis and management.

    abstract::Estrogenic compounds are the most important group of drugs that can induce hypertension. Studies have shown an incidence of significant hypertension amounting to less than 1% after 1 year of taking oral contraceptives and about 2% after 5 years. The ratio of the incidence of hypertension among ''takers'' to that of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197612030-00005

    authors: Stokes GS

    更新日期:1976-01-01 00:00:00